CTOs on the Move


 
Noom is the world`s leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom`s behavior change courses, including its virtual diabetes prevention program, which was the first of its kind to be recognized by the CDC. The Noom platform is already being used by leading healthcare and pharmaceutical companies to improve treatment outcomes for patients worldwide. The company is headquartered ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.noom.com
  • 229 West 28th Street Floor 9
    New York, NY USA 10001
  • Phone: 800.910.7375

Executives

Name Title Contact Details
James Zhou
Chief Information Security Officer and Senior Director, Systems Operations Profile
Takeaki Chijiiwa
Director, Information Security Profile
Richard Friedman
Chief Technology Officer Profile

Funding

Noom raised $58M on 05/06/2019
Noom raised $540M on 05/25/2021

Similar Companies

The Bright Spot for Health

The Bright Spot for Health is a Wichita, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Maxx Orthopedics

Maxx Orthopedics is a Plymouth Meeting, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NovaSom

NovaSom is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surface Oncology

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.

GetWellNetwork

GetWellNetwork, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bethesda, MD. To find more information about GetWellNetwork, Inc., please visit www.getwellnetwork.com